Abate As Industries Ltd
Incorporated in 1991, Abate As Industries
Ltd primarily operates in the eye healthcare segment through its super specialty hospitals
and optical outlets[1]
- Market Cap ₹ 186 Cr.
- Current Price ₹ 11.8
- High / Low ₹ 26.2 / 9.62
- Stock P/E 98.9
- Book Value ₹ 10.4
- Dividend Yield 0.00 %
- ROCE 0.65 %
- ROE 0.66 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.13 times its book value
Cons
- Promoter holding is low: 27.6%
- Earnings include an other income of Rs.2.73 Cr.
- Promoter holding has decreased over last 3 years: -4.31%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.08 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 | -0.01 | 0.00 | 0.00 | |
| 0.07 | 0.08 | 0.07 | 0.09 | 0.07 | 0.10 | 0.12 | 0.13 | 0.57 | 0.33 | 0.90 | 0.43 | 0.81 | |
| Operating Profit | 0.01 | 0.01 | -0.07 | -0.09 | -0.07 | -0.10 | -0.12 | -0.13 | -0.58 | -0.35 | -0.91 | -0.43 | -0.81 |
| OPM % | 12.50% | 11.11% | |||||||||||
| 0.00 | 0.00 | -4.77 | 0.08 | 0.05 | 0.11 | 0.15 | 0.14 | 0.17 | 0.00 | 0.00 | 0.97 | 2.73 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.00 | 0.00 | -4.85 | -0.02 | -0.02 | 0.00 | 0.02 | 0.01 | -0.42 | -0.35 | -0.91 | 0.54 | 1.92 |
| Tax % | 0.00% | 0.00% | 0.00% | -50.00% | 0.00% | -19.05% | 0.00% | 0.00% | 0.00% | ||||
| 0.00 | 0.00 | -4.84 | -0.01 | -0.02 | 0.00 | 0.02 | 0.01 | -0.34 | -0.35 | -0.91 | 0.54 | 1.88 | |
| EPS in Rs | 0.00 | 0.00 | -4.84 | -0.01 | -0.02 | 0.00 | 0.02 | 0.01 | -0.34 | -0.35 | -0.91 | 0.03 | 0.12 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -100% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 93% |
| 3 Years: | 53% |
| TTM: | 995% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 53% |
| 3 Years: | 14% |
| 1 Year: | 29% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.02 | 5.02 | 5.02 | 5.02 | 5.02 | 5.02 | 5.02 | 5.02 | 5.02 | 5.02 | 5.02 | 78.80 | 157.61 |
| Reserves | 0.28 | 0.27 | -4.57 | -4.32 | -4.35 | -4.36 | -4.38 | -4.35 | -4.65 | -5.01 | -5.92 | 85.24 | 6.90 |
| 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.12 | 0.21 | 0.62 | 1.22 | 1.58 | 1.59 | |
| 10.62 | 10.57 | 0.05 | 0.08 | 0.07 | 0.08 | 0.02 | 0.02 | 0.04 | 0.00 | 0.01 | 0.17 | 0.20 | |
| Total Liabilities | 15.92 | 15.86 | 0.50 | 0.79 | 0.74 | 0.74 | 0.66 | 0.81 | 0.62 | 0.63 | 0.33 | 165.79 | 166.30 |
| 0.93 | 0.92 | 0.02 | 0.02 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.21 | 0.21 | 0.08 | 0.08 | 0.08 | 0.06 | 0.02 | 0.04 | 0.00 | 0.00 | 0.00 | 164.40 | 164.40 |
| 14.78 | 14.73 | 0.40 | 0.69 | 0.66 | 0.67 | 0.63 | 0.77 | 0.62 | 0.63 | 0.33 | 1.39 | 1.90 | |
| Total Assets | 15.92 | 15.86 | 0.50 | 0.79 | 0.74 | 0.74 | 0.66 | 0.81 | 0.62 | 0.63 | 0.33 | 165.79 | 166.30 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.30 | 0.05 | -1.01 | -0.05 | -0.01 | 0.01 | -0.14 | -0.14 | -0.08 | -0.41 | -0.66 | -0.42 | |
| 0.00 | 0.00 | 1.03 | 0.00 | 0.00 | -0.02 | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | |
| 0.00 | 0.00 | 0.03 | 0.00 | -0.03 | 0.00 | 0.15 | 0.12 | 0.10 | 0.40 | 0.60 | 0.36 | |
| Net Cash Flow | -0.30 | 0.04 | 0.04 | -0.05 | -0.04 | -0.01 | 0.01 | -0.02 | 0.07 | -0.01 | -0.06 | -0.06 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 63,875.00 | 56,291.11 | -7,300.00 | -1,460.00 | 0.00 | |||||||
| Inventory Days | 0.00 | 0.00 | 0.00 | |||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 63,875.00 | 56,291.11 | -7,300.00 | -1,460.00 | 0.00 | |||||||
| Working Capital Days | 17,976.25 | 15,816.67 | 4,015.00 | -4,380.00 | -39,420.00 | |||||||
| ROCE % | 0.00% | 0.00% | -2.79% | -3.45% | -2.90% | 0.00% | 3.08% | 1.40% | -59.85% | -57.85% | -191.58% | 0.65% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations (Trading/Consultancy Phase) INR |
|
|||||||||||
| Contract Asset Receivables (representing active service engagements) INR in '000s |
||||||||||||
| Experience in Retail/Wholesale (Sky International Subsidiary) Years |
||||||||||||
| Number of Fully Functional Eye Hospitals Number |
||||||||||||
| Number of Optical LLPs/Distribution Points Number |
||||||||||||
| Strategic Target for International Eye Hospitals Number |
||||||||||||
| Students Educated (BSc Optometry Program cumulative since 2005) Number |
||||||||||||
| Trade Receivables Turnover Times |
||||||||||||
Documents
Announcements
-
Intimation Under Regulation 7(2) Of The SEBI (PIT) Regulations, 2015 As Received From Al Salama Eye Research Foundation
2h - Reg 7(2) insider trading disclosure dated 10.03.2026 by Al Salama Eye Research Foundation (Promoter Group) for scrip 531658.
-
Intimation Of Disclosure Under Regulation 7(2) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015
2 Mar - Al Salama Eye Research Foundation bought 82,202 shares, raising holding to 1,361,334 (0.86%) on 26-27 Feb 2026.
-
Announcement Under Regulation 30- Launch Of Abate'S Indigenous EMR & Integrated Eye Hospital Clinic Management System
17 Feb - Abate launches indigenous EMR Integrated Eye Hospital Clinic Management System via Prudential Management Services.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Feb - Submission of newspaper advertisement published regarding unaudited financial results for the quarter ended 31.12.2025
-
Board Meeting Outcome for Submission Of Outcome Of Board Meeting Held On 12Th February 2026
12 Feb - Board approved Q3 unaudited results; authorized capital increased to Rs 3,200 crore; appointed Harikumar V as independent director.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
AAIL is a multi-sector enterprise with a diverse portfolio in healthcare, education, retail, technology, real estate, and consultancy
services.